GlassScriptPhysician profile
Majed A Refaai
NPI 1730383274
$4,158,155.10
in general payments reported to CMS, 2019-2025
20 companies · $703K in 2025
The $703K reported for 2025 was more than what 99% of Clinical Pathology providers received nationally (typical 2025 total: $116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296K · 2020: $316K · 2021: $757K · 2022: $693K · 2023: $558K · 2024: $835K · 2025: $703K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2.0M · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Travel and Lodging: $8,743 · Food and Beverage: $3,178 · Honoraria: $1,600 · Gift: $50.25 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,047,800.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,706.40 |
| Travel and Lodging | $8,743.13 |
| Food and Beverage | $3,177.88 |
| Honoraria | $1,600.00 |
| Gift | $50.25 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $2,057,233.88 | 2019-2025 | Kcentra |
| Csl Plasma INC. | $2,007,600.00 | 2023-2025 | |
| Cerus Corporation | $60,465.31 | 2019-2025 | Intercept Blood System For Cryoprecipitation, Intercept Blood System For Platelets |
| Diagnostica Stago, INC | $28,664.80 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,920.00 | 2019 | |
| Hemosonics LLC | $860.22 | 2022-2024 | Quantra Qplus System, Qunatra Qplus System |
| Haemonetics Corporation | $734.32 | 2021-2025 | Teg6s Hemostasis System |
| Pharmacosmos Therapeutics INC. | $223.13 | 2024-2025 | Monoferric |
| Baxter Healthcare | $123.73 | 2019 | |
| Werfen USA LLC | $87.22 | 2023 | |
| Shire North American Group INC | $73.44 | 2019 | |
| Genzyme Corporation | $51.12 | 2025 | |
| Sanofi-Aventis U.S. LLC | $46.81 | 2019 | |
| Daiichi Sankyo INC. | $42.97 | 2022 | |
| Siemens Medical Solutions USA, INC. | $28.15 | 2025 | Automated Blood Coagulation Analyzer Cs-5100 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Majed Refaai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.